DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Pancreatic Ductal Adenocarcinoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
DRUG: Fluorouracil
DRUG: Gadolinium-Chelate
DRUG: Gemcitabine
DRUG: Irinotecan
DRUG: Leucovorin Calcium
DRUG: Nab-paclitaxel
DRUG: Oxaliplatin
DEVICE: Point-of-care portable perfusion phantom (P4)

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]